| T. W. Ponessa And Associates Counseling Services, Inc. | |
|
125 S 11th St Akron PA 17501-1509 | |
| (717) 560-7917 | |
| (717) 560-6452 |
| Full Name | T. W. Ponessa And Associates Counseling Services, Inc. |
|---|---|
| Speciality | Community/behavioral Health |
| Location | 125 S 11th St, Akron, Pennsylvania |
| Authorized Official Name and Position | Catherine A Deguire (CEO) |
| Authorized Official Contact | 7175607917 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| T. W. Ponessa And Associates Counseling Services, Inc. 2141 Oregon Pike Lancaster PA 17601-4604 Ph: (717) 560-7917 | T. W. Ponessa And Associates Counseling Services, Inc. 125 S 11th St Akron PA 17501-1509 Ph: (717) 560-7917 |
| NPI Number | 1710259015 |
|---|---|
| Provider Enumeration Date | 02/01/2012 |
| Last Update Date | 02/01/2012 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710259015 | NPI | - | NPPES |
| 100775933 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | 311720 (Pennsylvania) | Primary |
News Archive
Despite nearly universal awareness of report cards on risk-adjusted mortality rates of individual cardiac surgeons, cardiologists in New York State do not use these reports when making patient referral decisions.
arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).
An expert task force has created a new definition for epilepsy that refines the scope of patients diagnosed with this brain disease. The study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy, provides a greater level of detail to diagnose epilepsy by including individuals with two unprovoked seizures, and those with one unprovoked seizure and other factors that increase risk of seizure recurrence.
Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.
› Verified 2 days ago
Kaufman Counseling Associates Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 904 High St, Akron, PA 17501 Phone: 717-859-3908 Fax: 717-859-5659 |